A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Healthy

Interventions

BIOLOGICAL

INO-3401 + EP

All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.

Trial Locations (2)

Vince and Associates Clinical Research, Overland Park

Accelovance, Rockville